BillionToOne, Inc. Class A Common Stock (BLLN) Stock Price
BLLNStock
$98.12
Market Cap$4.63B
P/E621.14x
PEG Ratio—
Div yield—
Beta0.17
BLLN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)8.61%
Price vs S&P 500 (4W)-4.20%
VGM Score24.05
P/E Ratio (Annual)621.14x
BLLN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.16 | $0.36 | +124.25%(+$0.20) | |
| Q4 2025 | $0.17 | $0.15 | -10.55%(-$0.02) | |
| Q3 2025 | $0.16 | $0.91 | +468.75%(+$0.75) |
BLLN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.21
4.21
4.21
4.21
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About BillionToOne, Inc. Class A Common Stock
BillionToOne Inc develops precision diagnostic tests using its proprietary Quantitative Counting Templates technology to enable ultrasensitive DNA analysis. The company offers non-invasive prenatal screening and cancer monitoring solutions designed to provide greater accuracy and cost-effectiveness than traditional genetic testing. BillionToOne serves two large markets—prenatal screening and oncology—where demand for improved diagnostics continues to grow.